FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Bekeken· 09/21/23
OncLive® On Air
OncLive® On Air
0 abonnees
0
In

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Laat meer zien

 0 Comments sort   Sorteer op


Volgende